Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake

Front Endocrinol (Lausanne). 2023 Jul 24:14:1217021. doi: 10.3389/fendo.2023.1217021. eCollection 2023.

Abstract

Introduction: Oxyntomodulin (Oxm) hormone peptide has a number of beneficial effects on nutrition and metabolism including increased energy expenditure and reduced body weight gain. Despite its many advantages as a potential therapeutic agent, Oxm is subjected to rapid renal clearance and protease degradation limiting its clinical application. Previously, we have shown that subcutaneous administration of a fibrillar Oxm formulation can significantly prolong its bioactivity in vivo from a few hours to a few days.

Methods: We used a protease resistant analogue of Oxm, Aib2-Oxm, to form nanfibrils depot and improve serum stability of released peptide. The nanofibrils and monomeric peptide in solution were characterized by spectroscopic, microscopic techniques, potency assay, QCM-D and in vivo studies.

Results: We show that in comparison to Oxm, Aib2-Oxm fibrils display a slower elongation rate requiring higher ionic strength solutions, and a higher propensity to dissociate. Upon subcutaneous administration of fibrillar Aib2-Oxm in rodents, a 5-fold increase in bioactivity relative to fibrillar Oxm and a significantly longer bioactivity than free Aib2-Oxm were characterized. Importantly, a decrease in food intake was observed up to 72-hour post-administration, which was not seen for free Aib2-Oxm.

Conclusion: Our findings provides compelling evidence for the development of long-lasting peptide fibrillar formulations that yield extended plasma exposure and enhanced in vivo pharmacological response.

Keywords: GLP-1/glucagon; depot formulations; metabolic diseases; nanofibrils; peptides; self-assembly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Eating / physiology
  • Glucagon* / metabolism
  • Glucagon-Like Peptide 1* / pharmacology
  • Oxyntomodulin / chemistry
  • Oxyntomodulin / pharmacology
  • Peptide Hydrolases
  • Peptides / pharmacology
  • Receptors, Glucagon / metabolism

Substances

  • Glucagon
  • Glucagon-Like Peptide 1
  • Oxyntomodulin
  • Peptide Hydrolases
  • Peptides
  • Receptors, Glucagon

Grants and funding

This work was supported by AstraZeneca.